The Type 1 Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Type 1 Diabetes Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Type 1 Diabetes Market.
Some of the key takeaways from the Type 1 Diabetes Pipeline Report:
- Companies across the globe are diligently working toward developing novel Type 1 Diabetes treatment therapies with a considerable amount of success over the years.
- Type 1 Diabetes companies working in the treatment market are Arecor, Novo Nordisk, Novartis, ILTOO Pharma, ImCyse, Novartis, Zealand Pharma, Eli Lilly and Company, Dompe Farmaceutici, Prevention Bio, Zealand Pharma, Eledon Pharmaceuticals, Avotres, ImCyse, Histogen, Vertex Pharmaceuticals, Novo Nordisk, Panbela Therapeutics, Landos Biopharma, and others, are developing therapies for the Type 1 Diabetes treatment
- Emerging Type 1 Diabetes therapies in the different phases of clinical trials are- AT247, NNC0471-0119, MHS552, ILT-101, IMCY-0098, Iscalimab, LY3209590, Ladarixi, Teplizumab, Dasiglucagon, AT-1501, AVT001, IMCY-0098, Emricasan, VX-880, NNC0363 0845, Eflornithine, LABP 111, and others are expected to have a significant impact on the Type 1 Diabetes market in the coming years.
- In July 2022, Vertex Pharmaceuticals revealed that it has reached a final agreement in which it will pay $320 million in cash to acquire ViaCyte, a privately held biotechnology company dedicated to providing innovative stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D).
- In June 2022, Vertex Pharmaceuticals announced that the Phase I/II clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for individuals with type 1 diabetes (T1D) who have severe hypoglycemia and impaired hypoglycemia awareness, has been released from the clinical hold by the U.S. Food and Drug Administration.
- In April 2022, The National Institute of Diabetes and Digestive Kidney Disease (NIDDK) awarded $1.6 million to AVM Biotechnology as part of a Small Business Innovation Research (SBIR) grant so that the company could investigate the potential of its small chemical, AVM0703, to reverse Type 1 diabetes (T1D). With this most recent award, the business will be able to conduct more study on the use of AVM0703 as a combination treatment and as a single agent for the reversal of both established and recent onset T1D.
- In May 2022, With great pleasure, Sernova and Evotec announce their exclusive global strategic collaboration to create the greatest cell therapy treatment available for those with insulin-dependent diabetes. Through the collaboration, Sernova will have the only worldwide right to license Evotec’s iPSC-based beta cells for the treatment of type 1 and type 2 diabetes. Apart from signing the collaboration agreement, Evotec has invested €15 million in strategic equity and has committed to an additional €5 million.
- In March 2022, Declared: Jaguar Gene Therapy The JDRF T1D Fund, a venture philanthropy fund dedicated to discovering and funding the greatest cure-oriented therapeutics for Type 1 diabetes (T1D), and Samsung Ventures, an investment organization founded to support the development of innovative technologies, have both made investments in the company.
- In January 2022, Remedium Bio stated that company and the University of Massachusetts Boston have signed a Sponsored Research Agreement to finish pre-clinical effectiveness studies on pipeline prospects for Type 1 and Type 2 Diabetes. Working together, the teams will assess platform technology for diabetes treatment, which could have implications for the larger Remedium pipeline of gene therapies that could transform the condition by a single injection.
Type 1 Diabetes Overview
An autoimmune disease known as type 1 diabetes causes the pancreatic cells that make insulin to be destroyed by the immune system. What triggers this autoimmune reaction is unknown. Modifiable lifestyle factors are not associated with type 1 diabetes.
Get a Free Sample PDF Report to know more about Type 1 Diabetes Pipeline Therapeutic Assessment-
Emerging Type 1 Diabetes Drugs Under Different Phases of Clinical Development Include:
- AT247: Arecor
- NNC0471-0119: Novo Nordisk
- MHS552: Novartis
- ILT-101: ILTOO Pharma
- IMCY-0098: ImCyse
- Iscalimab: Novartis
- Dasiglucagon: Zealand Pharma
- LY3209590: Eli Lilly and Company
- Ladarixin: Dompe Farmaceutici
- Teplizumab: Prevention Bio
- AT-1501: Eledon Pharmaceuticals
- AVT001: Avotres
- IMCY-0098: ImCyse
- Emricasan: Histogen
- VX-880: Vertex Pharmaceuticals
- NNC0363 0845: Novo Nordisk
- Eflornithine: Panbela Therapeutics
- LABP 111: Landos Biopharma
Type 1 Diabetes Route of Administration
Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Type 1 Diabetes Molecule Type
Type 1 Diabetes Products have been categorized under various Molecule types, such as
- Small molecule
- Cell Therapy
- Small molecule
- Gene therapy
Type 1 Diabetes Pipeline Therapeutics Assessment
- Type 1 Diabetes Assessment by Product Type
- Type 1 Diabetes By Stage and Product Type
- Type 1 Diabetes Assessment by Route of Administration
- Type 1 Diabetes By Stage and Route of Administration
- Type 1 Diabetes Assessment by Molecule Type
- Type 1 Diabetes by Stage and Molecule Type
DelveInsight’s Type 1 Diabetes Report covers around 100+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Type 1 Diabetes product details are provided in the report. Download the Type 1 Diabetes pipeline report to learn more about the emerging Type 1 Diabetes therapies
Some of the key companies in the Type 1 Diabetes Therapeutics Market include:
Key companies developing therapies for Type 1 Diabetes are – Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Landos Biopharma, Zealand Pharma, Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy, SQZ Biotech, Enthera, and others.
Type 1 Diabetes Pipeline Analysis:
The Type 1 Diabetes pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Type 1 Diabetes with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 1 Diabetes Treatment.
- Type 1 Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Type 1 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 1 Diabetes market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Type 1 Diabetes drugs and therapies
Type 1 Diabetes Pipeline Market Drivers
- Rising prevalence of type-1 diabetes due to environmental and genetic factors, growing geriatric population, which is susceptible to type-1 diabetes, increasing prevalence of obesity, which is a contributing factor are some of the important factors that are fueling the Type 1 Diabetes Market.
Type 1 Diabetes Pipeline Market Barriers
- However, lack of awareness among patients regarding types of treatment available, strict approval process and side effects associated with the treatment may restrict market growth and other factors are creating obstacles in the Type 1 Diabetes Market growth.
Scope of Type 1 Diabetes Pipeline Drug Insight
- Coverage: Global
- Key Type 1 Diabetes Companies: Arecor, Novo Nordisk, Novartis, ILTOO Pharma, ImCyse, Novartis, Zealand Pharma, Eli Lilly and Company, Dompe Farmaceutici, Prevention Bio, Zealand Pharma, Eledon Pharmaceuticals, Avotres, ImCyse, Histogen, Vertex Pharmaceuticals, Novo Nordisk, Panbela Therapeutics, Landos Biopharma, and others
- Key Type 1 Diabetes Therapies: AT247, NNC0471-0119, MHS552, ILT-101, IMCY-0098, Iscalimab, LY3209590, Ladarixi, Teplizumab, Dasiglucagon, AT-1501, AVT001, IMCY-0098, Emricasan, VX-880, NNC0363 0845, Eflornithine, LABP 111, and others
- Type 1 Diabetes Therapeutic Assessment: Type 1 Diabetes current marketed and Type 1 Diabetes emerging therapies
- Type 1 Diabetes Market Dynamics: Type 1 Diabetes market drivers and Type 1 Diabetes market barriers
Request for Sample PDF Report for Type 1 Diabetes Pipeline Assessment and clinical trials
Table of Contents
1. Type 1 Diabetes Report Introduction
2. Type 1 Diabetes Executive Summary
3. Type 1 Diabetes Overview
4. Type 1 Diabetes- Analytical Perspective In-depth Commercial Assessment
5. Type 1 Diabetes Pipeline Therapeutics
6. Type 1 Diabetes Late Stage Products (Phase II/III)
7. Type 1 Diabetes Mid Stage Products (Phase II)
8. Type 1 Diabetes Early Stage Products (Phase I)
9. Type 1 Diabetes Preclinical Stage Products
10. Type 1 Diabetes Therapeutics Assessment
11. Type 1 Diabetes Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Type 1 Diabetes Key Companies
14. Type 1 Diabetes Key Products
15. Type 1 Diabetes Unmet Needs
16 . Type 1 Diabetes Market Drivers and Barriers
17. Type 1 Diabetes Future Perspectives and Conclusion
18. Type 1 Diabetes Analyst Views
20. About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States